Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Low Dose Enoxaparin Clear all
Terminated Phase 4 Interventional

Pre-operative Enoxaparin in the Surgical Management of Multi-trauma Patients Undergoing Orthopedic Surgical Procedures

NCT05081375
View directory record Official record
Conditions
Venous Thrombosis Deep (Limbs), Surgical Blood Loss
Interventions
Enoxaparin Injectable Product, Sodium chloride
Drug
Lead sponsor
Valleywise Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

NCT00641732
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
TAK-442, Enoxaparin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,045 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 3 Interventional

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

NCT00329628
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (BAY59-7939), Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

NCT02706249
View directory record Official record
Conditions
Venous Thormboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 2 Interventional

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254
View directory record Official record
Conditions
Venous Thrombosis
Interventions
PD 0348292, Enoxaparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Enoxaparin Metabolism in Reconstructive Surgery Patients

NCT02411292
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus, Reconstructive Surgery
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma

NCT03339349
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

NCT01094886
View directory record Official record
Conditions
Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
Interventions
Rivaroxaban
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Denver, Colorado • Hollywood, Florida • Tamarac, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

NCT02981472
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
28 Days to 17 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03891524
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 10, 2026, 4:12 AM EDT
Withdrawn Phase 2 Interventional

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

NCT00916669
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Etoposide, Cisplatin, enoxaparin sodium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
4
States / cities
Boston, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Not applicable Interventional Results available

Strategies for Anticoagulation During Venovenous ECMO

NCT04997265
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism
Interventions
Low intensity anticoagulation, Moderate Intensity Anticoagulation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Not applicable Interventional

Comparison of Apixaban Versus Enoxaparin

NCT06243510
View directory record Official record
Conditions
Bladder Cancer
Interventions
apixaban, enoxaparin
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 10, 2026, 4:12 AM EDT
Terminated Phase 4 Interventional Results available

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

NCT03296033
View directory record Official record
Conditions
Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
Interventions
Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 10, 2026, 4:12 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Lovenox With Aspirin in Thawed Blastocyst Transfer

NCT06133803
View directory record Official record
Conditions
Infertility, Female
Interventions
Lovenox, Aspirin, Embryo transfer
Drug · Procedure
Lead sponsor
Fertility Center of Las Vegas
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 3 Interventional

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

NCT00345618
View directory record Official record
Conditions
Embolism, Thrombosis
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 10, 2026, 4:12 AM EDT
Terminated Phase 4 Interventional Results available

Below Knee DVT Study

NCT03805672
View directory record Official record
Conditions
Deep Vein Thrombosis (DVT), Blood Clots
Interventions
Low Dose Enoxaparin, High Dose Enoxaparin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

NCT00697099
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 10, 2026, 4:12 AM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 10, 2026, 4:12 AM EDT
Terminated Not applicable Interventional Results available

Enoxaparin and/or Minocycline in Acute Stroke

NCT00836355
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Enoxaparin, Minocycline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Sep 10, 2026, 4:12 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

NCT00585182
View directory record Official record
Conditions
Obesity, Venous Thrombosis, Anticoagulants
Interventions
Enoxaparin 0.5 mg/kg once daily
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 10, 2026, 4:12 AM EDT